Barrios V Escobar C Calder&#243;n A Llisterri JL Alegr&#237;a E Mu&#241;iz J Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis J Cardiometab Syndr 2007 2 9-15 
Schillaci G Pirro M Vaudo G Gemelli F Marchesi S Porcellati C Prognostic value of the metabolic syndrome in essential hypertension J Am Coll Cardiol 2004 43 1817-1822 
Liu SJ Guo ZR Hu XS Wu M Chen FM Kang GD Risks for type-2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome the study from Jiangsu, China of 5 years follow-up Diabetes Res Clin Pract 2008 81 117-123 
Elliott WJ Meyer PM Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis Lancet 2007 369 201-207 
Bakris GL Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker J Clin Hypertens 2008 10 27-32 
Mancia G Laurent S Agabiti-Rosei E Ambrosioni E Burnier M Caulfield MJ Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document Blood Press 2009 18 308-347 
Bakris G Molitch M Hewkin A Kipnes M Sarafidis P Fakouhi K Bacher P Sowers J STAR investigators. differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome Diabetes Care 2006 29 2592-2597 
Kintscher U Bramlage P Paar WD Thoenes M Unger T Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two-armed study in 14&#8201;200 patients Cardiovasc Diabetol 2007 6 12 
Heidemann C Sun Q van Dam RM Meigs JB Zhang C Tworoger SS Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women Ann Intern Med 2008 149 307-316 
Sj&#246;holm A Nystr&#246;m T Inflammation and the etiology of type 2 diabetes Diabetes Metab Res Rev 2006 22 4-10 
Rubin D Claas S Pfeuffer M Nothnagel M Foelsch UR Schrezenmeir J s-ICAM-1 and s-VCAM-1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal Lipids Health Dis 2008 7 32 
Fabia MJ Abdilla N Oltra R Fernandez C Redon J Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24&#8201;h ambulatory blood pressure monitoring J Hypertens 2007 25 1327-1336 
Mason RP Marche P Hintze TH Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine Arterioscler Thromb Vasc Biol 2003 23 2155-2163 
Fogari R Preti P Zoppi A Mugellini A Corradi L Lazzari P Santoro T Derosa G Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients Intern Med 2008 47 1851-1857 
Alberti KG Zimmet P Shaw J The metabolic syndrome-a new worldwide definition Lancet 2005 366 1059-1062 
Hansson L Hedner T Dahl&#246;f B Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials Blood Press 1992 1 113-119 
Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia WHO: Geneva, Switzerland 2006 
Wallace TM Levy JC Matthews DR Use and abuse of HOMA modeling Diabetes Care 2004 27 1487-1495 
Law MR Wald NJ Morris JK Jordan RE Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials BMJ 2003 326 1427-1431 
Wald DS Law M Morris JK Bestwick JP Wald NJ Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11&#8201;000 participants from 42 trials Am J Med 2009 122 290-300 
Chrysant SG Melino M Karki S Lee J Heyrman R The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study Clin Ther 2008 30 587-604 
Punzi HA Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide Expert Rev Cardiovasc Ther 2009 7 229-239 
De Pablos-Velasco PL Mart&#237;nez-Mart&#237;n FJ Rodr&#237;guez-P&#233;rez F Prevalence of obesity in a Canarian community. Association with type 2 diabetes mellitus: the Gu&#237;a Study Eur J Clin Nutr 2002 56 557-560 
Borch-Johnsen K Wareham N The rise and fall of the metabolic syndrome Diabetologia 2010 53 597-599 
Ninomiya T Kiyohara Y Albuminuria and chronic kidney disease in association with the metabolic syndrome J Cardiometab Syndr 2007 2 104-107 
Gerstein HC Mann JF Yi Q Zinman B Dinneen SF Hoogwerf B Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals JAMA 2001 286 421-426 
Ibsen H Olsen MH Wachtell K Borch-Johnsen K Lindholm LH Mogensen CE Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study Hypertension 2005 45 198-202 
Bakris G Stockert J Molitch M Zhou Q Champion A Bacher P Risk factor assessment for new onset diabetes: literature review Diabetes Obes Metab 2009 11 177-187 
Chobanian AV Bakris GL Black HR Cushman WC Green LA Izzo JL Jr The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report JAMA 2003 289 2560-2572 
Kaplan NM The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide Hypertension 2009 54 951-953 
Eriksson JW Jansson PA Carlberg B H&#228;gg A Kurland L Svensson MK Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) study Hypertension 2008 52 1030-1037 
Cooper-DeHoff RM Wen S Beitelshees AL Zineh I Gums JG Turner ST Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications Hypertension 2010 55 61-68 
Alderman MH New-onset diabetes during antihypertensive therapy Am J Hypertens 2008 21 493-499 
Alderman MH Is new-onset diabetes mellitus important? Yes, but&#8230; High Blood Pres &amp; Cardiovasc Prev 2008 15 5-8 
Bakris G Molitch M Zhou Q Sarafidis P Champion A Bacher P Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study J Cardiometab Syndr 2008 3 18-25 
Aguilar D Solomon SD K&#248;ber L Rouleau JL Skali H McMurray JJ Newly diagnosed and previously known diabetes mellitus and 1&#8211;year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial Circulation 2004 110 1572-1578 
Jamerson K Weber MA Bakris GL Dahl&#246;f B Pitt B Shi V Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 2008 359 2417-2428 
Matsui Y Eguchi K O&#8242;Rourke MF Ishikawa J Miyashita H Shimada K Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients Hypertension 2009 54 716-723 
Fliser D Buchholz K Haller H Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertension patients with microinflammation Circulation 2004 110 1103-1107 
Smith DH Neutel JM Lacourci&#232;re Y Kempthorne-Rawson J Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements J Hypertens 2003 21 1291-1298 
